In vitro and preclinical models of ccRCC have shown that ACE2 inhibits tumor proliferation, with the heptapeptide angiotensin (Ang-(1–7)) potentially mediating this effect. This evidence concerns the gene ACE2 and nonpapillary renal cell carcinoma.